AMGN vs ZBIO
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. ZBIO: Clinical-stage immunology company developing obexelimab, a novel bifunctional monoclonal antibody targeting B cells for the treatment of autoimmune diseases.
Side-by-side fundamentals
| Metric | AMGN | ZBIO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $407.44 | $26.24 | |
| Market cap | $220.3B | $1.7B | |
| P/E as of 2026-10-08 | 25.30 | n/a | |
| Net margin FY2025, SEC XBRL | +21.0% | -3777.4% | AMGN higher |
| Operating margin FY2025, SEC XBRL | +24.7% | -3830.6% | AMGN higher |
| ROE FY2025, SEC XBRL | +89.1% | -156.0% | AMGN higher |
| ROA FY2025, SEC XBRL | +8.5% | -98.5% | AMGN higher |
| Debt / equity as of 2026-09-03 | 4.90 | 1.04 | ZBIO lower |
| Revenue growth (YoY) as of 2026-09-03 | +9.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +11.8% | -55.3% | AMGN higher |
| Dividend yield as of 2026-09-03 | +2.6% | n/a | |
| Dividend streak (yrs) SEC XBRL | 15 | 0 | AMGN higher |
| Beta as of 2026-09-03 | 0.42 | 1.30 | |
| 1-year return as of 2026-10-08 close | +38.3% | +1.3% | AMGN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.